Why the study?
Cardiovascular and cerebrovascular diseases are major noncommunicable diseases with increasing prevalence, and the therapeutic potentials and molecular mechanisms of the ginseng extract ginsenoside Rb1 warranted review.
Does Ginsenoside Rb1 exert protective effects in models of cardiovascular and cerebrovascular diseases?
Does Ginsenoside Rb1 exert protective effects in models of cardiovascular and cerebrovascular diseases?
Ginsenoside Rb1 exhibits pleiotropic protective effects on the cardiovascular system in preclinical models, highlighting its potential as a therapeutic agent for cardiovascular and cerebrovascular diseases.
G-Rb1 may support CCVD management; leaves open efficacy and safety pending rigorous RCTs.
Cardiovascular and cerebrovascular diseases (CCVDs), which are circulatory system diseases caused by heart defects and vascular diseases, are the major noncommunicable diseases affecting global public health. With the improvement of economic level and the change of human lifestyle, the prevalence of CCVDs continues to increase. Ginseng ( Panax ginseng C. A. Mey.) was widely used in traditional diseases due to its supposed tonic properties. Ginsenoside Rb 1 (G-Rb 1 ) is the most abundant active ingredient with multiple pharmacological effects extracted from ginseng , which has been shown to have potential benefits on the cardiovascular system through a variety of mechanisms, including anti-oxidation, anti-inflammatory, regulation of vasodilation, reduction of platelet adhesion, influence of calcium ion channels, improvement of lipid distribution, involving in glucose metabolism and controlling blood sugar. This review reviewed the protective effects of G-Rb 1 on CCVDs and its potential mechanisms, such as atherosclerosis (AS), hypertension, coronary heart disease (CHD), ischemic stroke (IS) and periocular microvascular retinopathy. Finally, we reviewed and reported the results of in vivo and in vitro experiments using G-Rb 1 to improve CCVDs, highlighted its efficacy, safety, and limitations.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: